New Hope Network is part of the Informa Markets Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Medical Research Institute Introduces Glucotize Controlled-Release Formulation of Alpha-Lipoic Acid

SAN FRANCISCO, Mar 30, 2005 (BUSINESS WIRE) -- Medical Research Institute (MRI), an innovator in nutraceutical approaches for diabetes, today announced the availability of Glucotize(TM), the only patented (three US patents awarded; additional applications filed), controlled-release formulation of the antioxidant alpha-lipoic acid.

Recently, results from a collaborative study between groups from the Mayo Clinic and the Russian Medical Academy reported that alpha-lipoic acid rapidly and significantly reduced the frequency and severity of symptoms from diabetic polyneuropathy (Ametov et al Diabetes Care 2003 26:770-6), and in other work, has been reported to improve whole-body glucose metabolism and insulin sensitivity in individuals with type 2 diabetes. Intravenous infusions of ALA have been used by physicians in Germany for more than 25 years to treat neuropathy, a common diabetic complication, and one that causes significant pain and discomfort.

While other manufacturers offer alpha-lipoic acid, it is not controlled release, a limitation that means alpha-lipoic acid is eliminated from the body very quickly -- in as little as 30 minutes -- significantly hampering its efficacy. MRI's Glucotize(TM) is a unique oral formulation whose controlled-release formulation remains in the body for hours rather than minutes.

"Alpha-lipoic acid has long been recognized for its beneficial impact on diabetic neuropathy," said Dr. Ira D. Goldfine, director, Division of Diabetes & Endocrine Research, Mount Zion Medical Center, University of California San Francisco. "However, the current oral formulations typically remain in the blood only a very short time, requiring either multiple daily doses or intravenous infusions. While more clinical studies are needed with controlled-release oral formulations of alpha-lipoic acid, it is clear that such preparations should be very helpful."

Glucotize(TM) has been evaluated in two previous clinical studies, and is currently being evaluated in three additional clinical studies at major university Diabetes Centers. For more information on these studies and on product availability, please visit

About MRI and MRI Products

Headquartered in San Francisco, California, Medical Research Institute is a pioneer in the research, development, and clinical validation of therapeutic nutraceuticals for those suffering from diabetes and its complications. These, and the company's other innovative nutraceuticals with cutting-edge delivery technologies, are available nationwide through General Nutrition Center (GNC) stores and online at

Hide comments


  • Allowed HTML tags: <em> <strong> <blockquote> <br> <p>

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.